Both transactions will be funded through internal accruals and are expected to be completed by the end of September 2026
Under the deal, Novartis will have multiple options to secure exclusive global rights to develop subcutaneous versions of selected products using berahyaluronidase alfa (ALT-B4).
The deal will give SK Biopharmaceuticals access not only to opakalim but also to Biohaven’s Kv7 discovery platform and related compounds
The latest round brings AusperBio’s total fundraising to $360 million since 2024
The new entity to be called Ennature Bio Pharma Limited reported net revenue of Rs. 90 crore in the June 2026 quarter
With India's medical-devices market projected to reach around US$30 billion by 2030, the exhibition highlighted the growing role of domestic manufacturing alongside global technology partnerships
Belgian biotech to complete preclinical development, prepare lead candidate for GMP manufacturing and double its R&D team
Company deepens collaborations with Novo Nordisk, Sanofi and Roche while advancing its international portfolio and innovation pipeline
Partnership gives Cipla development and commercialisation rights for TQB2102 across India, South Africa and five other emerging markets
CEPI aims to advance at least two Bundibugyo vaccines toward Emergency Use Authorisation and WHO Prequalification, while building preparedness for potential future outbreaks
WISE is available as a liquid that can also be cast into moulds to create micron-scale structures, enabling applications across imaging and microstructured device workflows
Much of the existing microbiome research has focused on European and North American populations, leaving South Asia, home to nearly one-fourth of the world's population, comparatively underrepresented
The transaction also includes warrants that become exercisable upon FDA approval of the drug for pulmonary hypertension
The latest transaction takes Natco Pharma’s total investment in Cambridge, Massachusetts-based eGenesis to $22 million
Company executives outline three-pillar AI strategy, ecosystem-building through 10 centres of excellence, and long-term investment plans as India's shift toward complex biotherapeutics accelerates
Rs. 76 crore deal lifts Piramal's stake from 33.33% to 74%, bringing vaccine and biologics CDMO capabilities fully in-house as part of its integrated service offering
Rapid Media Prototyping Service (RaMP) is designed to help biopharma development teams accelerate timelines, generate critical process data and prepare for subsequent GMP manufacturing
Iberdomide combination shows 41% MRD-negative complete response rate in Phase III trial, doubling the rate seen with standard comparator regimen
USPTO patent covers ultrasound-guided administration of Stempeucel-OA for Grade II and III knee osteoarthritis
Under the revised plan, the facility will combine biologics and biosimilar manufacturing capabilities with its existing small-molecule oncology line
Subscribe To Our Newsletter & Stay Updated
